Technical Analysis for CRL - Charles River Laboratories International, Inc.

Grade Last Price % Change Price Change
D 187.90 0.97% 1.80
CRL closed up 0.97 percent on Wednesday, November 20, 2024, on 86 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
MACD Bearish Centerline Cross Bearish 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Reached Oversold Weakness 0.97%
Down 3 Days in a Row Weakness 0.97%
Down 4 Days in a Row Weakness 0.97%
Down 5 Days in a Row Weakness 0.97%
Oversold Stochastic Weakness 0.97%
MACD Bearish Signal Line Cross Bearish 0.21%
NR7 Range Contraction 0.21%
Inside Day Range Contraction 0.21%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low about 20 hours ago
Down 1% about 20 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
Up 1% about 22 hours ago
Rose Above Previous Day's High 2 days ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Charles River Laboratories International, Inc. Description

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment is involved in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, research animal diagnostic services, endotoxin and microbial detection products and services, and avian vaccine products and services. The PCS segment provides preclinical services, including both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: S&P 500 Biotechnology Life Sciences Pharmaceutical Drug Discovery Lab Testing In Vitro Metabolism Toxicology Laboratory Services Diagnostic Services Contract Research Organizations Clinical Services Pathology Pharmacokinetics Toxicology Testing Detection Products Drug Metabolism Pathology Services Pre Clinical Development Vaccine Products

Is CRL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 275.0
52 Week Low 176.48
Average Volume 753,991
200-Day Moving Average 219.26
50-Day Moving Average 195.05
20-Day Moving Average 193.83
10-Day Moving Average 201.50
Average True Range 8.11
RSI (14) 44.13
ADX 23.03
+DI 27.17
-DI 31.05
Chandelier Exit (Long, 3 ATRs) 205.69
Chandelier Exit (Short, 3 ATRs) 200.81
Upper Bollinger Bands 221.48
Lower Bollinger Band 166.18
Percent B (%b) 0.39
BandWidth 28.53
MACD Line -0.14
MACD Signal Line 1.52
MACD Histogram -1.6558
Fundamentals Value
Market Cap 9.64 Billion
Num Shares 51.3 Million
EPS 9.22
Price-to-Earnings (P/E) Ratio 20.38
Price-to-Sales 2.70
Price-to-Book 3.45
PEG Ratio 1.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 195.05
Resistance 3 (R3) 194.39 191.35 193.86
Resistance 2 (R2) 191.35 189.53 191.68 193.46
Resistance 1 (R1) 189.63 188.41 190.49 190.28 193.06
Pivot Point 186.59 186.59 187.02 186.92 186.59
Support 1 (S1) 184.86 184.77 185.73 185.52 182.74
Support 2 (S2) 181.82 183.64 182.15 182.34
Support 3 (S3) 180.10 181.82 181.94
Support 4 (S4) 180.75